Paclitaxel Trials Boost PAD Treatment Effectiveness
“`html
SWEDEPAD Re-opens Paclitaxel Safety Discussion, Finds Drug-Coated Devices Do Not Improve Outcomes
Table of Contents
Published September 1, 2025, at 20:34:57 PDT
Updated as needed to reflect new developments.
What Happened?
The Swedish Drug and Therapeutics Products Agency (Läkemedelsverket),known as SWEDEPAD,has revisited the safety of paclitaxel-coated devices used in peripheral artery disease (PAD) treatment.their recent review, published in September 2025, concludes that these devices do not demonstrate improved outcomes compared to bare-metal stents or balloon angioplasty. Vascular News reported on the findings.
This re-evaluation stems from ongoing concerns raised in 2018 regarding a potential link between paclitaxel and increased mortality rates. Initial analyses, including those from the U.S. Food and Drug Administration (FDA), suggested a possible signal of increased mortality, prompting further investigation. The FDA issued a safety interaction in 2019 outlining the ongoing review.
Why It Matters: The Paclitaxel Controversy
Paclitaxel is a chemotherapy drug that inhibits cell division. When coated onto stents or balloons used in PAD treatment, it’s intended to prevent restenosis – the re-narrowing of arteries after they’ve been opened. PAD affects an estimated 8.5 million adults in the United States, causing pain, disability, and increased risk of heart attack and stroke. The Centers for Disease Control and Prevention (CDC) provides complete details on PAD.
The initial concerns about paclitaxel’s safety led to meaningful debate within the vascular surgery and interventional cardiology communities. The potential for increased mortality, even if small, raised questions about the risk-benefit ratio of using these devices. SWEDEPAD’s latest findings add weight to the argument that the risks may outweigh the benefits, especially given the availability of alternative treatments.
SWEDEPAD’s Findings in Detail
SWEDEPAD’s review analyzed data from multiple clinical trials and real-world registries. Their analysis focused on comparing outcomes - including mortality, limb amputation, and restenosis - between patients treated with paclitaxel-coated devices and those treated with bare-metal stents or balloon angioplasty. The agency found no statistically significant evidence that paclitaxel-coated devices improved outcomes. In some analyses,there was a trend towards *worse* outcomes in the paclitaxel group,although this was not consistently observed.
The agency specifically noted the challenges in interpreting the data due to variations in study design,patient populations,and follow-up durations. However, they concluded that the available evidence does not support the routine use of paclitaxel-coated devices for PAD.
Impact on Patients and Physicians
These findings are likely to influence clinical practice, possibly leading physicians to reconsider their use of paclitaxel-coated devices. Patients with PAD should discuss the risks and benefits of all available treatment options with their doctors. Alternatives include bare-metal stents, balloon angioplasty, and, in some cases, surgical bypass grafting.
The FDA continues to monitor the safety of paclitaxel-coated devices and is expected to review SWEDEPAD’s findings.Further research is needed to fully understand the long-term effects of paclitaxel and to identify which patients, if any, might benefit from these devices.